Newsletter Tool

PM Tracker

Today’s Big News

Jul 12, 2024

Pfizer's obesity pill news leaves analysts wanting, biotech investors cheering

AbbVie's Humira loses some ground in high-stakes battle against biosimilars: report

Senate unanimously endorses legislation targeting pharma 'patent thickets'

Know Labs delivers positive early clinical data for its needle-free glucose sensor

Immutep tries to regain pep as cancer subgroup data show path forward—with a long list of caveats

Abecma competition, Sotyktu pricing pressure and IRA: Analysts outline Bristol Myers’ top challenges

Chutes & Ladders—Pfizer's Mikael Dolsten steps down as AbbVie's R&D org switches leaders

Featured

Pfizer's obesity pill news leaves analysts wanting, biotech investors cheering

By Annalee Armstrong

Pfizer gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release formulation of oral med danuglipron will be advanced into dose optimization studies.

AbbVie's Humira loses some ground in high-stakes battle against biosimilars: report

By Zoey Becker

With ten biosimilar options in play, AbbVie's star immunology drug lost 13% of its total market share since March, according to a new Samsung Bioepis report.

Senate unanimously endorses legislation targeting pharma 'patent thickets'

By Zoey Becker

The bill looks to limit the number of patents that companies can assert in litigation on individual products. It's intended to crack down on "patent thickets," which can delay and thwart generic competition.

Know Labs delivers positive early clinical data for its needle-free glucose sensor

By Conor Hale

The company said its digital, non-invasive and machine learning-driven approach can correctly determine if a user’s glucose levels are too high, too low or just right 93.37% of the time.

Immutep tries to regain pep as cancer subgroup data show path forward—with a long list of caveats

By Nick Paul Taylor

Immutep has spotted a potential niche for its LAG3 drug candidate, reporting phase 2b data in a subset of head and neck cancer patients to partly wipe away the stain left by an earlier readout.

Abecma competition, Sotyktu pricing pressure and IRA: Analysts outline Bristol Myers’ top challenges

By Angus Liu

Several challenges across Bristol Myers Squibb’s business have Leerink Partners analysts worried about the drugmaker—despite a few promising growth opportunities they identified. The analysts have lowered their revenue forecast for the company’s key growth products Sotyktu, Zeposia, Abecma, Opdualag, and the newly acquired KarXT.

Chutes & Ladders—Pfizer's Mikael Dolsten steps down as AbbVie's R&D org switches leaders

By Annalee Armstrong,Darren Incorvaia

After leading Pfizer’s R&D unit through the pandemic, Chief Scientific Officer Mikael Dolsten, M.D., Ph.D., is heading out.

Fierce podcasts

Don’t miss an episode

A look at Big Pharma’s top-paid CEOs

In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma's 10 highest-paid CEOs.”

The state of digital health investment in 2024

Designing with neurodiversity in mind

The best biopharma M&A deals

Resources

Whitepaper

An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing

In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.

The “Best Practice Organization” & Its Importance for Success in Today’s Biopharma Industry

In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers.

Sponsored by: Blue Matter, strategic consultants in the life sciences